Saltar al contenido
Merck
  • An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis.

An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis.

PloS one (2014-10-23)
Yu-Hua Chao, Han-Ping Wu, Kang-Hsi Wu, Yi-Giien Tsai, Ching-Tien Peng, Kuan-Chia Lin, Wan-Ru Chao, Maw-Sheng Lee, Yun-Ching Fu
RESUMEN

Sepsis remains an important cause of death worldwide, and vigorous immune responses during sepsis could be beneficial for bacterial clearance but at the price of collateral damage to self tissues. Mesenchymal stem cells (MSCs) have been found to modulate the immune system and attenuate sepsis. In the present study, MSCs derived from bone marrow and umbilical cord were used and compared. With a cecal ligation and puncture (CLP) model, the mechanisms of MSC-mediated immunoregulation during sepsis were studied by determining the changes of circulating inflammation-associated cytokine profiles and peripheral blood mononuclear cells 18 hours after CLP-induced sepsis. In vitro, bone marrow-derived MSCs (BMMSCs) and umbilical cord-derived MSCs (UCMSCs) showed a similar morphology and surface marker expression. UCMSCs had stronger potential for osteogenesis but lower for adipogenesis than BMMSCs. Compared with rats receiving PBS only after CLP, the percentage of circulating CD3+CD4+CD25+ regulatory T (Treg) cells and the ratio of Treg cells/T cells were elevated significantly in rats receiving MSCs. Further experiment regarding Treg cell function demonstrated that the immunosuppressive capacity of Treg cells from rats with CLP-induced sepsis was decreased, but could be restored by administration of MSCs. Compared with rats receiving PBS only after CLP, serum levels of interleukin-6 and tumor necrosis factor-α were significantly lower in rats receiving MSCs after CLP. There were no differences between BMMSCs and UCMSCs. In summary, this work provides the first in vivo evidence that administering BMMSCs or UCMSCs to rats with CLP-induced sepsis could increase circulating CD3+CD4+CD25+ Treg cells and Treg cells/T cells ratio, enhance Treg cell suppressive function, and decrease serum levels of interleukin-6 and tumor necrosis factor-α, suggesting the immunomodulatory association of Treg cells and MSCs during sepsis.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Dexametasona, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
3-Isobutil-1-metilxantina, ≥99% (HPLC), powder
Sigma-Aldrich
3-Isobutil-1-metilxantina, ≥99%, BioUltra
Sigma-Aldrich
Dexametasona, ≥98% (HPLC), powder
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
5(6)-Carboxyfluorescein diacetate N-succinimidyl ester, BioReagent, suitable for fluorescence, ≥90% (HPLC)
Sigma-Aldrich
Dexametasona, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Dexametasona, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Supelco
Dexametasona, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Dexametasona, meets USP testing specifications
USP
Indomethacin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
5-Carboxy-fluorescein diacetate N-succinimidyl ester, for fluorescence, ≥95.0% (HPLC)
Sigma-Aldrich
Dexametasona, tested according to Ph. Eur.
Indomethacin, European Pharmacopoeia (EP) Reference Standard
Dexametasona, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexametasona, VETRANAL®, analytical standard
Dexametasona, European Pharmacopoeia (EP) Reference Standard
Dexametasona, European Pharmacopoeia (EP) Reference Standard
Dexametasona, British Pharmacopoeia (BP) Assay Standard